RGEN - REPLIGEN CORP
IEX Last Trade
146.97
4.930 3.354%
Share volume: 0
Last Updated: Tue 24 Dec 2024 05:59:56 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
$142.04
4.93
3.47%
Fundamental analysis
19%
Profitability
9%
Dept financing
33%
Liquidity
75%
Performance
12%
Performance
5 Days
1.72%
1 Month
0.61%
3 Months
5.27%
6 Months
19.33%
1 Year
-19.58%
2 Year
-11.77%
Key data
Stock price
$146.97
DAY RANGE
$142.04 - $146.03
52 WEEK RANGE
$120.98 - $211.13
52 WEEK CHANGE
-$20.01
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/29/2024
Company detail
CEO: Tony J. Hunt
Region: US
Website: repligen.com
Employees: 2,020
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: repligen.com
Employees: 2,020
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company sells its products to life sciences, biopharmaceutical companies; laboratory researchers; and contract manufacturing organizations.
Recent news